Canopy Growth Corporation
CGCHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Canopy Growth Corporation (CGC) is listed under Drug Manufacturers - Specialty & Generic. Valued at $476.0M, CGC is a small-cap name in its sector. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works.
Market Cap
$476.0M
Beta
2.39
P/E (TTM)
—
P/E (Fwd)
-14.51
EPS (TTM)
$-1.35
EPS (Fwd)
$-0.07
ROE
-48.5%
ROA
-2.6%
Cash
$371.5M
Total Debt
$255.1M
Free CF
-$26.0M
52W Change
-18.5%
Annual Financials
Cash vs Debt
Canopy Growth Corporation holds $371.5M in cash against $255.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$26.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -48.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $475.7M (2022) to $269.0M (2025), a 43% decline worth watching.
Canopy Growth Corporation's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CGC.